Screener
MoonLake Immunotherapeutics MLTX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands, except share and per share data) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Numerator | ||
| Net loss attributable to controlling interests shareholders | $(69,707) | $(39,944) |
| Denominator | ||
| Total weighted average number of outstanding shares | 71,273,650 | 63,233,788 |
| Net loss per share – basic and diluted | $(0.98) | $(0.63) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's shares (diluted)?
- MoonLake Immunotherapeutics (MLTX) reported shares (diluted) of 71.3M in Q1 2026.
- How has MoonLake Immunotherapeutics's shares (diluted) changed year-over-year?
- MoonLake Immunotherapeutics's shares (diluted) increased by 12.7% year-over-year, from 63.2M to 71.3M.
- What is the long-term trend for MoonLake Immunotherapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's shares (diluted) has grown at a 22.9% compound annual growth rate (CAGR), from 111.5M to 254.4M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about MoonLake Immunotherapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude